Puff Biofeedback to Reduce Smoking Reinforcement

Sponsor
Rutgers, The State University of New Jersey (Other)
Overall Status
Recruiting
CT.gov ID
NCT05644002
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
88
1
2
17.3
5.1

Study Details

Study Description

Brief Summary

The purpose of the study is to examine the effects of a novel bio-behavioral paradigm, entitled, Puff Topography Biofeedback Training, compared to a control condition, in reducing stress-induced smoking reinforcement.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Puff Topography Biofeedback Training
  • Behavioral: Control
N/A

Detailed Description

Smokers with emotional distress are particularly vulnerable to smoking reinforcement due to various biopsychological factors that contribute to deficits in emotion regulation and heightened reward processing, which undermine cessation efforts. Differences in puffing behavior may correspond with changes in cardiorespiratory parameters that may promote self-regulation and reduce craving.

This study is a between-subjects experimental test of Puff Topography Biofeedback Training (PTBT) and its ability to modify puff topography and cardiorespiratory activity during stress-precipitated smoking, and in turn, reduce acute smoking reinforcement.

Participants will be randomized to either PTBT or a Control condition and will complete two smoking trials on two successive days. The first smoking trial (Visit 1) will allow participants to gain familiarity with the task. The second smoking trial (Visit 2) will be completed following acute laboratory stress induction (stress-precipitated smoking trial).

The primary study aims are to test the effect of PTBT vs. Control as assessed via acute changes in stress-precipitated smoking reinforcement and changes in puffing behavior and cardiorespiratory parameters.The results of this high pre-intervention study could inform the subsequent development of a novel intervention strategy for improving quit outcomes in a treatment-resistant population.

The primary study aims are to test the effect of PTBT vs. Control in terms of: (a) objective puff topography parameters; (b) subjective reinforcement; and (c) whether physiological indices reflective of smoking reinforcement differ between conditions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
88 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
A Puff Topography Biofeedback Paradigm to Reduce Stress-Precipitated Smoking Reinforcement
Actual Study Start Date :
Mar 21, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Control

In this condition, participants are instructed to smoke as usual while attending to control stimuli presented to them on a computer monitor.

Behavioral: Control
Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes. Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.
Other Names:
  • Attention Control
  • Experimental: Puff Topography Biofeedback Training (PTBT)

    In this condition, participants are provided instructions on how to puff their cigarette via a computer-assisted paradigm.

    Behavioral: Puff Topography Biofeedback Training
    Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes. Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.

    Outcome Measures

    Primary Outcome Measures

    1. Cigarette Purchase Task [Second Training Day following the Stress-Induction and Intervention (Smoking Task) i.e. post intervention, average 1 day.]

      The Short-Cigarette Purchase Task (CPT) will be used to assess smoking reinforcement in response to stress-precipitated smoking. The CPT is based on progressive-ratio operant schedules wherein participants self-report their hypothetical cigarette consumption at various levels of price. Hypothetical purchasing will be based on the "last cigarette smoked". Five key behavioral economic indices of demand can be obtained from the CPT: intensity (number of cigarettes consumed at zero cost), Omax (peak expenditure for a cigarette), Pmax (price at maximum expenditure for a cigarette), breakpoint (cost whereby consumption is suppressed to zero), and elasticity (the degree to which consumption decreases with increasing price).

    2. Modified Cigarette Evaluation Questionnaire [Second Training Day following the Stress-Induction and Intervention (Smoking Task) i.e. post intervention, average 1 days.]

      The Modified Cigarette Evaluation Questionnaire (mCEQ) will be used to assess subjective smoking reinforcement. The mCEQ is a self-report measure that assesses how respondents feel about the "last cigarette smoked" with subscales that index liking (cigarette satisfaction), wanting (craving reduction), and learning (psychological reward). Scores on each of the mCEQ subscales range from 1 to 7. Higher scores on each of the subscales of the mCEQ reflect greater subjective smoking satisfaction, craving reduction, and psychological reward, respectively. Changes in the mCEQ from during Visit 1, to post stress-precipitated smoking, during Visit 2, will be compared.

    Secondary Outcome Measures

    1. Changes in Cardiac Vagal Control [Second Training Day prior to Stress-Induction, and following Stress-Induction during Intervention (Smoking Task), average 1 day.]

      Continuous electrocardiograph (ECG) and respiration data will be sampled at 1,000Hz during the adaptation period and stress-precipitated smoking periods. Changes in cardiac vagal control will be calculated as the difference in heart rate variability in the high frequency range (i.e., 0.12-0.40 Hz), which reflects parasympathetic control via the vagus nerve.

    2. Puff topography [Second Training Day following Stress-Induction during Intervention (Smoking Task), average 1 day.]

      Puff topography indices will be objectively measured with the CReSS micro (Plowshare Technologies, Borgwaldt KC, Inc), a hand-held device that has a sterilized flow meter mouthpiece that is connected to a pressure transducer, which converts pressure into a digital signal that is sampled at 1,000Hz. Average Puff duration (sec) will be used to assess mechanism engagement from PTBT.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18-55

    • Daily smoking ≥ 8 cigarettes/day verified by carbon monoxide analysis of breath sample ≥ 8 ppm

    • Smoking within 30 minutes of waking

    • English fluency.

    Exclusion Criteria:
    • Current smoking cessation treatment

    • Past-month reduction of cigarettes/day by ≥50%

    • Moderate or severe non-nicotine substance use disorder

    • Past-year psychiatric instability (e.g., psychosis, mania)

    • Severe visual, hearing, or cognitive impairments

    • Medical condition that could impact stress reactivity or physiology

    • Current regular use of medication that could affect cardiorespiratory function (e.g., beta blockers, benzodiazepines; note-use of SSRIs/SNRIs is permitted if dose is stable ≥ 6 wks).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rutgers. The State University of New Jersey New Brunswick New Jersey United States 08901

    Sponsors and Collaborators

    • Rutgers, The State University of New Jersey
    • National Institute on Drug Abuse (NIDA)

    Investigators

    • Principal Investigator: Teresa Leyro, PhD, Rutgers, The State University of New Jersey
    • Principal Investigator: Samantha Farris, PhD, Rutgers, The State University of New Jersey

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Teresa M. Leyro, Ph.D., Associate Professor, Rutgers, The State University of New Jersey
    ClinicalTrials.gov Identifier:
    NCT05644002
    Other Study ID Numbers:
    • Pro2020000645
    • R21DA052723
    First Posted:
    Dec 9, 2022
    Last Update Posted:
    Dec 9, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Teresa M. Leyro, Ph.D., Associate Professor, Rutgers, The State University of New Jersey

    Study Results

    No Results Posted as of Dec 9, 2022